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ABSTRACT 
G Protein-Coupled Estrogen Receptor (GPER)-Mediated Relaxation of Coronary Arteries is 
Mitigated by Phosphorylation of ERK1/2 
 
 
Rebecca Harlow 
Department of Biomedical Sciences 
Texas A&M University 
 
Research Advisor: Dr. Guichun Han 
Department of Veterinary Physiology and Pharmacology  
Texas A&M University 
 
GPER is a membrane-bound estrogen receptor, distinct from ERα or ERβ, and exerts 
genomic and non-genomic effects. GPER’s effect on the cardiovascular system has been 
controversial; evidence indicates it relaxes arteries, whereas other findings suggest it contracts 
arteries. Our objective is to better understand the dual nature of GPER. Previously, our work 
demonstrated that G-1 stimulates cAMP production. I hypothesize GPER mediates relaxation 
response through cAMP and constriction via ERK1/2. Isometric tension studies were used to 
measure GPER-mediated coronary tone response in porcine coronary arteries. Western blots 
were applied to detect pERK1/2 in primary cell culture of smooth muscle cells. The identity of 
smooth muscle cells was validated by immunohistochemistry techniques using α actin as a 
marker. G-1 inhibited phosphorylation; however, under adenylyl cyclase inhibition by SQ22536, 
G-1 stimulated phosphorylation of ERK1/2. The effect of G-1 was blocked by G36, a GPER 
inhibitor. A time course of E2 (100 nM) demonstrated E2 acutely stimulated phosphorylation of 
ERK1/2. Tension studies demonstrated that G-1 caused concentration-dependent relaxation of 
PGF2α (1 µM) precontracted, endothelium denuded, coronary arteries. PD98059, a MEK 
inhibitor that blocks the phosphorylation of ERK1/2, led to further relaxation than G-1 alone. I 
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conclude that phosphorylation of ERK1/2 lessens the coronary artery relaxation caused by 
GPER.  
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NOMENCLATURE 
 
CASMC Coronary artery smooth muscle cells 
CHD  Coronary heart disease 
ERα   Estrogen receptor α  
ERβ  Estrogen receptor β  
ERK1/2 Extracellular signal-regulated protein kinases 1 and 2 
E2  Estrogen, estradiol 
GPER  G-protein coupled estrogen receptor 
HRT  Hormone replacement therapy 
pERK1/2 Phosphorylated ERK1/2 
PGF2α  Prostaglandin F2α  
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CHAPTER I 
INTRODUCTION 
 
Heart disease is the number one killer of women in the United States, according to the 
CDC [1]. Contrary to popular belief, the gender gap of cardiovascular disease decreases with 
age, even affecting more women than men in the elderly population [2]. By redefining the male-
normalized standards for diagnosis [3], clinicians have identified “atypical” pattern of heart 
attacks and stroke and now recognize the epidemic, spurring the scientific community to 
investigate underlying risk factors and prevention, pathogenesis and therapy. 
 
Hormone replacement therapy 
Because women typically do not develop coronary heart disease (CHD) until after 
menopause [4], the estrogen present before menopause was considered to be a protective 
vasodilator. Dilation in coronary arteries allows better blood supply to the cardiac muscle itself, 
lowering the risk of cardiac hypoxia and possible heart attack [5]. The theory led to the 
reasonable assumption that simple replacement via hormone replacement therapy (HRT) would 
continue this protection [6, 7]. And in some ways, estrogen replacement therapy exhibits marked 
benefits, such as slowing progression of osteoporosis by limiting bone demineralization [8], 
treating depression associated with the hormonal change of menopause [9] and preventing eye 
disease [10]. 
However, risks of estrogen HRT were noticed as early as 1991, including higher incidence 
of gallbladder disease [11] and breast cancer [12, 13]. Save its beneficial reduction of LDL levels 
[14], postmenopausal estrogen HRT has been shown to not only fail to maintain the anticipated 
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protective effect [15, 16], but in many cases increase the risk of cardiovascular disease: increased 
plasma levels of inflammatory C Reactive Protein (CRP) [17] and increased incidence of 
cardiovascular events such as venous thromboembolism [18], heart attack and stroke [19]. In 
fact, the massive randomized trial by Women’s Health Initiative studying postmenopausal 
estrogen hormone therapy was terminated due to emerging preliminary data of these risks, 
particularly in patients receiving combination therapy of estrogen and progestin [8]. 
Respectively, postmenopausal estrogen HRT is presently not standard clinical practice but used 
cautiously and under extenuating circumstances [20]. 
 
Estrogen  
It is near universal knowledge that estrogen is the female sex hormone. Indeed, estrogen 
is pivotal in female reproductive health as it is synergistic in luteinization and ovulation in the 
ovaries and permissive to progesterone’s effect on the uterus. Yet with receptors present in a 
variety of tissue types, estrogen exerts a wide array of cellular effects outside the reproductive 
realm, such as inhibiting proliferation and stimulating maturation of chondrocytes [21] and 
stimulating endothelial nitric oxide synthase (eNOS) in endothelium via transactivation of EGFR 
[22]. To this end, estrogen explains the disparity addressed by gender-specific medicine. Perhaps 
a better label of estrogen would be simply “the female hormone.”  
The idea that estrogen is a vasodilator began in 1884 when John Mackenzie amusingly 
linked sinus irritation with menstruation (conversely, the estrogen present at ovulation dilates the 
nasal passages) [23]. Modern research has greatly expounded its investigation of effects of 
estrogen on vascular cells: Raddino et al. found that blood flow in the heart was improved by 
acute administration of estrogen via decreasing resistance in the coronary vasculature walls [24], 
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a mechanism later delineated to involve relaxation of vascular smooth muscle cells, both directly 
and indirectly via stimulation of vasodilator nitric oxide release from endothelium [25] . 
However, in 2005, White et al. noted a vasoconstrictor nature of estrogen of coronary arteries in 
vitro [26]. Such seemingly contradictory results have brought estrogen to the forefront of 
scientific debate: is estrogen a pure vasodilator or a pure vasoconstriction? Alternatively, I posit 
that evidence supports a dual role of estrogen in the regulation of arterial tone, mediating both 
relaxation and contraction of vascular smooth muscle cells.   
 
GPER 
Estrogen has two classical receptors, ERα and ERβ. Both of these nuclear receptors 
trigger genomic responses via endothelium growth factor receptor (EGFR activation), causing 
long-term vasodilatory effects, likely via nitric oxide production [22]. Yet several discrepancies 
led to the suspicion of an estrogen receptor mechanistically different from ERα/ERβ [27]. For 
instance, estrogen been linked to the cAMP, a G-protein associated pathway [28], and 
nongenomic activation of eNOS [22], as well as non-nuclear subcellular localizations such as the 
plasma membrane [29]. 
Before its ultimate renaming to G protein-coupled estrogen receptor (GPER) by Prossnitz 
and Arterburn in 2007 [30], various instances of simultaneous discovery prompted several 
notable aliases: Owman et al. discovered the cDNA, “CMKRL2” [31] which was isolated and 
cloned by Carmeci et al. who coined the cloned protein “GPR30” (as it was an orphaned G 
protein-coupled receptor without its cognate ligand) [32]; Hawkins et al. identified it in 2000 as 
an estrogen receptor, naming it ERλ, [33], triggering the piecing together of the various identities 
[34, 35]. 
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Though this 7-transmembrane α helical protein is primarily associated with the plasma 
membrane, other subcellular localizations such as the endoplasmic reticulum have been 
controversially reported [34, 36]. GPER has been found in most human tissues [37]: endothelium 
[38], lung, heart, lymphoid tissue [39], brain and peripheral nervous system [31], bone [40], renal 
tubules [41] as well as cancers of the breast [32], ovarian [42], endometrium [43], and some 
thyroid [44].  
It is unusual for one ligand to target both nuclear receptors (classic steroid model) as well 
as plasma membrane receptors (such as GPCRs), which are typically reserved for hydrophilic 
ligands. Yet lipophilic estrogen binds to GPER and exerts effects via adenylyl cyclase and cAMP 
cascade, likely by MLCP activation [45]. Unlike other GPCRs, GPER also exerts genomic 
effects, likely via transactivation of EGFR [27] and ERK1/2 [46]. Mediating both rapid non-
genomic and slow lingering non-genomic effects might explain the complexity and seeming 
incongruity among studies. 
 
Objective 
In my study, I investigated GPER as the possible underlining mechanism by which HRT 
causes adverse effects, e.g. higher incidence of heart attack and stroke [8]. Researchers have 
well-established GPER-mediated vasodilation, yet further investigation of GPER-mediated 
vasoconstriction has been largely overlooked. My objective is to further elucidate the dual nature 
of GPER by studying vascular tone in porcine coronary arteries. I hypothesize that GPER 
mediates relaxation via cAMP and constriction via ERK1/2.  
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CHAPTER II 
MATERIALS AND METHODS 
 
Experimental Rationale 
 First, I aim to link GPER activation with the phosphorylation of ERK1/2, accomplished 
through western blot techniques. Second, I aim to use isometric tension studies to prove a causal 
relationship between ERK1/2 phosphorylation (under various conditions of inhibition) and 
changes of vascular tone in coronary arteries. I propose that though often masked by GPER-
mediated vasodilation, GPER mediates vasoconstriction via ERK1/2 pathway. 
 
 
Table 1. Estrogen Receptor Ligands. All estrogen receptors bind estrogen with estriadiol (E2) 
selectivity. G-1 binding to ERα and ERβ is insignificant, thus G-1 is regarded as GPER-specific, 
Ligand/agent Receptor Notes and Significance 
Estrogen ERα/ERβ agonist 
GPER agonist 
Estradiol (E2) selectivity 
CI182,780 
(fulvestrant), 
ERα/ERβ “pure” antagonist 
(eliminating constitutive 
activity) 
GPER agonist 
Vasoconstrictor via ERα/ERβ and a 
vasodilator via GPER 
 
G-1 ERα/ERβ: insignificant binding 
GPER: agonist 
GPER-selective agonist 
G36 GPER antagonist Reverses effects seen by GPER. 
When paired with E2, isolates 
ERα/ERβ-specific effects 
SQ22536 Inhibits adenylyl cyclase Inhibits cAMP effects mediated by 
GPER (effects seen attributed to 
ERK1/2 pathway) 
PD98059 MEK inhibitor Upstream blockade of ERK1/2 
activation 
EGF EGFR Positive control 
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and is used to distinguish GPER activity from ERα/ERβ activity. ICI182,780 (fulvestrant), a 
“pure” ERα/ERβ antagonist binds with extraordinary high affinity, distorting the receptor shape 
and disrupting its constitutive activity [47] (unlike general antagonists), yet acts as an agonist to 
GPER [48, 49]. According to Han et al., this divergence of effects among the estrogen receptors 
explains how estrogen can be both a vasoconstrictor via ERα/ERβ and a vasodilator via GPER 
[50]. SQ22536 inhibits adenylyl cyclase, thus blocking cAMP-mediated effects (used in this 
study to block the vasodilation pathway). PD98059 inhibits MEK, the kinase directly responsible 
for activating ERK1/2.  
 
 
Isolation of porcine coronary arteries 
           Freshly collected porcine hearts were obtained from a local slaughterhouse, K&C meat 
processing, and transported in 4°C Krebs solution. Coronary arteries were grossly dissected in 
4°C Krebs solution. 
 
Culture of porcine coronary artery smooth muscle cells 
Grossly dissected coronary arteries were sliced open and mechanically endothelium-
denuded by a cotton swab. Smooth muscle cells were enzymatically dispersed from vessel wall 
with collagenase, soybean trypsin inhibitor, and dissociation buffer mixture and shaken for 2 
hours in a 37°C water bath, then washed repeatedly with 4°C PBS buffer. Primary cultured 
porcine coronary artery smooth muscle cells were treated with penicillin antibiotic (100 µg/ml) 
and streptomycin antifungals (100 µg/ml) then allowed to grow in Medium 231 with Smooth 
Muscle growth Supplement (GIBCO USA) in a 37°C humidified incubator under 5% CO2-95% 
O2. Coronary artery smooth muscle cells were cultured to 80% confluence and underwent 8-9 
passages of culture.  
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Validation of smooth muscle cells 
The identity of smooth muscle cells was validated by immunohistochemistry using α 
actin as a marker of smooth muscle cells, and DAPI (4', 6-diamidino-2-phenylindole) stain of 
nuclei.  
 
Figure 1. Immunohistochemistry slide of smooth muscle cells. Nuclei are stained blue, α actin 
in green, thus validating the cells’ identity as smooth muscle cells.  
 
Western blot  
Cell cultures were serum deprived for 48 hours, then set in vehicle in phenol red free 
MEMα medium and treated for 1-2 days with various combinations of agonists and antagonists: 
pretreated with adenylyl cyclase inhibitor SQ22536, selective GPER agonist G-1 (1 µM) and 
GPER antagonist G36 (10 µM), and EGF (10 ng/ml) as positive control. Similar experiment was 
done with E2 (100 nM) at various times of administration (2, 5, 15, 30 min), without E2 as 
negative control, and EGF (10 ng/ml) as positive control, however under no adenylyl cyclase 
inhibition. 
In order to stop the drug action, cells were washed with cold PBS, placed on ice, lysed for 
5 min with RIPA lysis buffer with protease and phosphatase inhibitor. Next, cells were lifted 
from plates and centrifuged at 4°C for 20 min and stored in -20°C overnight. Loading buffer was 
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added to samples before boiling for 5 min. 15% gel with 4-12 uM size specificity was loaded and 
run at 200 volts for 40 min, then proteins were transferred onto blotting membrane using transfer 
buffer before being run at 100 volts for 90 min. Membrane was set in nonfat 5% milk and probed 
with 1:1000 rabbit pERK1/2 (primary antibody), rocked in fridge overnight. The next day, 
membrane was washed with cold PBS, incubated with 4% BSA-PBS for 1 hour, before 
administration of 1:5000 anti-rabbit IgG (secondary antibody) conjugated with FITC (PA1-
29388 Thermo Scientific Pierce) for 1 hour at room temperature in the dark. After three washes 
with PBS, the coverslips were mounted for imaging. 
 
Isometric tension studies 
Porcine left anterior descending (LAD) artery was dissected, endothelium-denuded, and 
cut into 3mm rings which were then mounted on isometric myographs (DMT) filled with 
modified Krebs-Henseleit buffer bubbled with 95% O2-5% CO2 (pH = 7.4) at 37°C. Optimal 
resting tension was determined then used to equilibrate rings for 90 min before checking rings’ 
contractility by administration of PGF2α, a vasoconstrictor prostaglandin. To block 
phosphorylation of ERK1/2, MEK inhibitor PD98059 was added to the treatment group 30 min 
prior to the measurement of a complete G-1 (selective GPER agonist) relaxation response (1 to 
3000 nM).  
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Fig 2. Wire myograph system (DMT). Photograph of equipment used in large vessel isometric 
tension studies. 
 
Statistical analysis 
Data are presented as means ± standard deviation (SD). For statistical analysis, Prism 
program (GraphPad Software Inc., San Diego, CA) performed one-way or two-way analysis of 
variance (ANOVA), followed by Tukey's multiple comparison test paired with repeated 
measures. The level of statistically significance was set as P < .05.  
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CHAPTER III 
RESULTS 
 
G-1 and pERK1/2 
Western blot technique was employed to detect the pERK1/2 in porcine coronary artery 
smooth muscle cells treated with GPER agonist G-1, with and without adenylyl cyclase 
inhibition by SQ22536.  
 
 
Figure 3. GPER activation by G-1 alone inhibits phosphorylation of ERK1/2. Under adenylyl 
cyclase inhibition by SQ22536, G-1 stimulates phosphorylation of ERK1/2. Western blot 
detection of phosphorylated ERK1/2 (pERK1/2). Porcine coronary artery smooth muscle cells 
were pretreated with or without adenylyl cyclase inhibitor SQ22526, then incubated with DMSO 
(solvent control), G-1 (1 µM), G36 (10 µM) + G-1 (1 µM), and EGF (10 ng/ml, positive control).  
 
GPER activation with by G-1 alone inhibits phosphorylation or ERK1/2; an effect 
blocked by the GPER antagonist G36. However, under adenylyl cyclase inhibition by SQ22536, 
G-1 stimulated phosphorylation of ERK1/2. These results are consistent with my theory that 
GPER is a dual regulator of two converse pathways: blocking cAMP activation enhances 
ERK1/2 activation. 
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E2 and pERK1/2 
Unlike G-1, which is GPER specific, E2 binds to all three of the estrogen receptors (ERα, 
ERβ and GPER) thus convoluting findings and variables. Therefore, I seek to elucidate a small 
piece of the puzzle: estrogen’s relationship with phosphorylating ERK1/2. 
 
 
Figure 4. GPER activation by E2 stimulates phosphorylation of ERK1/2. Western blot 
detection of ERK1/2 of coronary artery smooth muscle cells incubated either without E2 
(negative control, first column), with E2 (100 nM) administered at 2, 5, 15, or 30 min, or with 
EGF (10 ng/ml, positive control). Top row is phosphorylated ERK1/2, bottom row in total 
ERK1/2. 
 
Contrary to G-1 treatment alone (see Fig. 3), treatment of E2 (100 nM) acutely stimulates 
phosphorylation of ERK1/2. 
 
G-1’s effect on vascular tone via ERK1/2 
Performing an isometric tension study, I tested the effects of G-1-induced GPER 
activation on vascular tone under two conditions: G-1 alone, and G-1 with MEK inhibitor 
PD98059. Since MEK is the kinase directly responsible for phosphorylation (and thus activation) 
of ERK1/2, addition of PD98059 should reduce or reverse the actions of ERK1/2; if vascular 
tone is partially mediated by phosphorylation of ERK1/2, then the two condition groups should 
yield varying effects on vascular tone. 
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Figure 5. G-1 treatment induces porcine coronary artery smooth muscle cell relaxation, and 
PD98059 further increases G-1 –induced relaxation.  Left: Typical trace of an isometric tension 
study. Initial basal vascular tone of coronary artery cross-sectional ring was defined as 0 mN 
(with force as a measure of constriction), before vessel was precontracted by PGF2α (1 µM). 
Right: Percent relaxation effect by administration of G-1, with and without addition of PD98059 
(1 µM), a MEK inhibitor. The percent decrease of contraction caused by G-1 administration, as 
compared to the maximal contraction induced by PGF2α relaxation, was calculating for each 
data point using the formula: 
 
% Relaxation = (Fmaximal contraction induced by PGF2α) - (Fcontraction after G-1 added)  x  100 
(Fmaximal contraction induced by PGF2α) 
 
Results are expressed as mean relaxation effect ± SE of 6 experiments. **P < 0.01, compared 
with the G-1 only group by two-way ANOVA analysis.  
 
G-1-alone treatment induced relaxation of precontracted coronary arteries in a 
concentration-dependent manner, whereas blocking phosphorylation of ERK1/2 by the 
administration of PD98059 increased the relaxation effect of G-1. Thus, it is reasonable to infer 
that the physiological converse is true: permitting phosphorylation of ERK1/2 mitigates GPER-
mediated vasorelaxation. Taken together, these data support a vasoconstrictor component of 
GPER, and suggests this action to be mediated in part by phosphorylation of ERK1/2.  
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Summary of results 
1. GPER activation by G-1 (1 µM) alone inhibits phosphorylation of ERK1/2. However, under 
adenylyl cyclase inhibition by SQ22536, G-1 stimulates phosphorylation of ERK1/2. 
2. GPER activation by E2 (100 nM) acutely stimulates phosphorylation of ERK1/2, an opposite 
effect of G-1 treatment alone. 
3. G-1 treatment induces coronary artery relaxation in a concentration-dependent manner. 
However, upstream inhibition increases the relaxation effect of G-1, indicating a 
vasoconstriction component of GPER activated by G-1. 
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CHAPTER IV 
DISCUSSION 
 
Phosphorylation of ERK1/2 lessens the coronary artery relaxation caused by GPER. Such 
mitigation implies a vasoconstrictive component of GPER that is mediated by ERK1/2 – a 
conclusion bolstering the support of the dual-regulator model of GPER. By mediating both 
vasorelaxation via cAMP and vasoconstriction via ERK1/2 cascade, GPER explains the 
paradoxical nature of estrogen on vascular tone. In these studies, vasodilation appears to be a 
more prominent pathway, possibly masking the vasoconstrictive component.  
It is interesting to note that G-1 and E2 had opposing effects on the phosphorylation of 
ERK1/2: inhibition by G-1, stimulation by E2, or G-1 under adenylyl cyclase inhibition. This 
contrast might be explained by the difference of target receptors between G-1 and E2, an idea 
seemingly congruent with research area of selective estrogen receptor modulators (SERM).  
A deeper understanding of GPER can lead to groundbreaking pharmacological therapies 
to inhibit estrogen’s deleterious effect of vasoconstriction, while still permitting its many 
beneficial effects for the rest of the body. For instance, combination therapy with a GPER-
selective antagonist to block the vasoconstrictive component of GPER activation might enable 
the safe resurgence of estrogen replacement therapy. Women seeking relief from hot flashes and 
protection from osteoporosis could resupply estrogen without risk of heart disease. Women 
requiring hysterectomies could have smoother hormonal transitions.  
With more research of the scope, mechanism, and regulation of GPER’s effects in the 
body, the full power of estrogen may be harnessed. 
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